Mark RubinSummaryAffiliation: Cornell University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
ETS rearrangements in prostate cancerMark A Rubin
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA
Asian J Androl 14:393-9. 2012....
Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studiesHarveer Dev
Lefrak Center of Robotic Surgery and Institute for Prostate Cancer, Brady Foundation Department of Urology, Weill Cornell Medical College, New York, NY, USA
J Transl Med 9:121. 2011..We seek to establish the integrity of our biobanking process by measuring the RNA quality of specimens derived from robotic-assisted laparoscopic radical prostatectomy...- FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing dataAndrea Sboner
Program in Computational Biology and Bioinformatics, Yale University, 300 George Street, New Haven, CT 06511, USA
Genome Biol 11:R104. 2010..It also has a module to identify exact sequences at breakpoint junctions. FusionSeq detected known and novel fusions in a specially sequenced calibration data set, including eight cancers with and without known rearrangements... - Common gene rearrangements in prostate cancerMark A Rubin
Weill Cornell Medical College, 1300 York Ave, Room C 410 A, New York, NY 10021, USA
J Clin Oncol 29:3659-68. 2011.... - Targeted therapy of cancer: new roles for pathologists--prostate cancerMark A Rubin
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
Mod Pathol 21:S44-55. 2008..However, in 2007, the mainstay of treatment for advanced PCA remains androgen ablation therapy as originally introduced in the early 1940s... - N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancerDorothee Pflueger
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
Neoplasia 11:804-11. 2009..Broader implications of this study support the use of RNA sequencing to discover novel cancer translocations... - Molecular sampling of prostate cancer: a dilemma for predicting disease progressionAndrea Sboner
Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA
BMC Med Genomics 3:8. 2010..Hence, we sought to develop a molecular panel for prostate cancer progression by reasoning that molecular profiles might further improve current clinical models... 
APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancersAmy V Gerstein
Department of Pathology, Institute of Cancer Genetics, Columbia University, New York, New York, USA
Genes Chromosomes Cancer 34:9-16. 2002..These results suggest that CTNNB1 signaling plays a critical role in the development of a significant fraction of prostate cancers. Moreover, they provide the first evidence that hTRCP1 plays a role in human neoplasia...- KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasisGoutham Narla
Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York 10029, USA
J Clin Invest 118:2711-21. 2008..Together, these findings demonstrate that KLF6-SV1 expression levels in PCa tumors at the time of diagnosis can predict the metastatic behavior of the tumor; thus, KLF-SV1 may represent a novel therapeutic target... - A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer riskGoutham Narla
Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA
Cancer Res 65:1213-22. 2005.... - Distinct genomic aberrations associated with ERG rearranged prostate cancerFrancesca Demichelis
Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY 10065
Genes Chromosomes Cancer 48:366-80. 2009..This study provides further support to define a distinct molecular subtype of prostate cancer based on the presence of ETS gene rearrangements... - SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancerDavid S Rickman
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York 10021, USA
Cancer Res 69:2734-8. 2009..g., trans-splicing)... - Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate modelSue Ellen Touma
Department of Pharmacology, Weill Cornell Medical College of Cornell University, 1300 York Avenue, New York, NY 10065, USA
Biochem Pharmacol 78:1127-38. 2009..Our data indicate that this reduction in ALDH1A2 protein is an early event in human prostate cancer... - Visual cues as a surrogate for tactile feedback during robotic-assisted laparoscopic prostatectomy: posterolateral margin rates in 1340 consecutive patientsAshutosh K Tewari
LeFrak Center of Robotic Surgery and Institute of Prostate Cancer, James Buchanan Brady Foundation Department of Urology, Weill Medical Collage, Cornell University, 525 East 68th Street, Starr 900, New York, NY 10065, USA
BJU Int 106:528-36. 2010..e. the ability to feel when vision is greatly enhanced, as the lack of tactile feedback during RALP is often cited as a disadvantage of robotic surgery, interfering with a surgeon's ability to make intraoperative oncological decisions... - ERG rearrangement metastasis patterns in locally advanced prostate cancerSven Perner
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York 10065, USA
Urology 75:762-7. 2010..Recent studies characterizing ERG-rearranged PCa possessing intrafocal homogeneity but interfocal heterogeneity support this hypothesis... - Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohortRaquel Esgueva
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA
Mod Pathol 23:539-46. 2010..Incorporation of these less common ERG rearranged prostate cancer fusion assays could further increase the sensitivity of the current PCR-based approaches... - Antibody-based detection of ERG rearrangement-positive prostate cancerKyung Park
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA
Neoplasia 12:590-8. 2010..Given the ease of performing IHC versus FISH, ERG protein expression may be useful for molecularly subtyping prostate cancer based on ERG rearrangement status and suggests clinical utility in prostate needle biopsy evaluation... - Collagen XXIII expression is associated with prostate cancer recurrence and distant metastasesJacqueline Banyard
Vascular Biology Program, Department of Surgery, Children s Hospital, Boston, MA 02115, USA
Clin Cancer Res 13:2634-42. 2007..The purpose of this study was to determine the expression of collagen XXIII in human prostate cancer and investigate its relationship with disease progression... - Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancerRohit Mehra
Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Mod Pathol 20:538-44. 2007.... - Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancerKirsten D Mertz
Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
Int J Cancer 123:569-76. 2008..Distinct molecular subtypes of ccRCC with prognostic relevance were identified, and the CK7/CK19 expressing subtype is associated with better outcome... - Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancerPamela L Paris
Department of Urology, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA
Neoplasia 8:1083-9. 2006..Matched primaries and lymph node metastases showed very similar copy number profiles that are distinct from primary tumors that fail to metastasize... - Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancerBharathi Laxman
Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Neoplasia 8:885-8. 2006..These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer... - The polycomb group protein EZH2 is involved in progression of prostate cancerSooryanarayana Varambally
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Nature 419:624-9. 2002..Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression... - TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancerSven Perner
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, EBRC 442A, 221 Longwood Avenue, Boston, MA 02115-6110, USA
Cancer Res 66:8337-41. 2006..The deletion as cause of TMPRSS2:ERG fusion is associated with clinical features for prostate cancer progression compared with tumors that lack the TMPRSS2:ERG rearrangement... - Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissueMatthias D Hofer
Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Arch Pathol Lab Med 130:989-96. 2006..The metastasis-associated gene 1 (MTA1) is overexpressed in several human cancers. Recent reports suggest that MTA1 may play a role in cancer progression either through transcription repression and/or hormone receptor interactions... - Defining aggressive prostate cancer using a 12-gene modelTarek A Bismar
Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
Neoplasia 8:59-68. 2006..0015). This study demonstrates that cross-platform models can lead to predictive models with the possible advantage of being more robust through this selection process... - How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in SwedenOve Andrén
Department of Urology, Orebro University Hospital, Orebro, Sweden
J Urol 175:1337-40. 2006..Therefore, identifying prognostic factors is increasingly important, notably among men diagnosed with localized prostate cancer, because many of them may not require aggressive treatment... - TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasionSven Perner
Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115 6110, USA
Am J Surg Pathol 31:882-8. 2007..Furthermore, its clinical application as a biomarker and ancillary diagnostic test is promising given its high specificity... - Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalitiesScott E Eggener
J Urol 178:2260-7. 2007..We encourage the investigation of focal therapy in select men with low risk prostate cancer in prospective clinical trials that carefully document safety, functional outcomes and cancer control... - TMPRSS2-ETS fusion prostate cancer: biological and clinical implicationsFrancesca Demichelis
Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
J Clin Pathol 60:1185-6. 2007 - A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosisSven Perner
Mod Pathol 21:1056; author reply 1056-7. 2008 - The role of SPINK1 in ETS rearrangement-negative prostate cancersScott A Tomlins
Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Cancer Cell 13:519-28. 2008..We identified the aggressive 22RV1 cell line as a SPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement-negative prostate cancers... - Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implicationsJuan Miguel Mosquera
Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
Clin Cancer Res 14:3380-5. 2008..This may have significant clinical implications given that TMPRSS2-ERG fusion prostate cancer is associated with a more aggressive clinical course... - Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancerSunita R Setlur
Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
J Natl Cancer Inst 100:815-25. 2008.... - Detection of early prostate cancer using a hepsin-targeted imaging agentKimberly A Kelly
Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
Cancer Res 68:2286-91. 2008..HPN imaging may provide a new method for detection of prostate cancer... - Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapyYilin C Neeley
Department of Urology, Surgery, and Pathology, University of Michigan Ann Arbor, Michigan, USA
Prostate 68:715-27. 2008..Failure of cancer immunotherapy is essentially due to immunological tolerance to tumor-associated antigens (TAAs), as these antigens are also expressed in healthy tissues... - Role of the TMPRSS2-ERG gene fusion in prostate cancerScott A Tomlins
Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Neoplasia 10:177-88. 2008..Our results support previous work suggesting that TMPRSS2-ERG fusions mediate invasion, consistent with the defining histologic distinction between PIN and prostate cancer... - Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohortLorelei A Mucci
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
Cancer Epidemiol Biomarkers Prev 17:249-51. 2008..We quantified protein expression of the nine genes in tumors to classify progression risk. Accounting for clinical prognostic factors, the nine-gene model did not provide discrimination to predict lethal and indolent prostate cancer... - Integrative biology of prostate cancer progressionScott A Tomlins
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Annu Rev Pathol 1:243-71. 2006..This review addresses candidate genes involved in prostate cancer pathogenesis in a biological and clinical context and demonstrates how integrated analysis of high-throughput data augments our understanding of prostate cancer... - Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interactionShao Yong Chen
Cancer Biology Program, Hematology Oncology Division, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
Mol Cell Biol 26:929-39. 2006.... - Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancerPhillip G Febbo
Duke Institute for Genome Sciences and Policy, Division of Medical Oncology Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 12:152-8. 2006.... - The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancerRainer Kuefer
Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0944, USA
Clin Cancer Res 9:6447-52. 2003..The purpose of this study was to evaluate an 80 kDa proteolytic fragment of E-cadherin as a potential biomarker for prostate cancer progression and to identify putative proteases that are responsible for the cleavage of E-cadherin... - Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferationsLakshmi P Kunju
Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
Am J Clin Pathol 120:737-45. 2003..Most HGPINs show diffuse moderate P504S staining. AAH may show focal P504S staining. We recommend using P504S along with morphologic examination and conventional basal cell markers... - Prevention of prostate cancer with finasterideMark A Rubin
N Engl J Med 349:1569-72; author reply 1569-72. 2003 - Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasisZheng Fu
Program in Immunology, School of Medicine, University of Michigan, Ann Arbor 48109 0940, USA
J Natl Cancer Inst 95:878-89. 2003..We examined whether RKIP functions as a suppressor of metastasis... - Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisionsCaleb P Nelson
Departments of Urology and Pathology, University of Michigan, Ann Arbor, MI, USA
Urol Oncol 21:213-8. 2003..Tabulated 5-year PSA-free survival outcomes, stratified by these preoperative parameters, provide a basis for preoperative counseling of patients regarding postprostatectomy cancer control expectations... - Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumorsHassan Chaib
Department of Urology, The University of Michigan, Ann Arbor 48109, USA
Genes Chromosomes Cancer 37:306-13. 2003.... - Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cellsAlexandre De La Taille
Department of Urology, Assistance Publique des Hôpitaux de Paris CHU Mondor, 94000 Creteil, France
Clin Cancer Res 9:1801-7. 2003.... - Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancerDaniel R Rhodes
Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
J Natl Cancer Inst 95:661-8. 2003..19, 95% CI = 1.50 to 6.77; P =.003). CONCLUSION: EZH2:ECAD status was statistically significantly associated with prostate cancer recurrence after radical prostatectomy and may be useful in defining a cohort of high-risk patients... - Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cellsMing Zhou
Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
Am J Surg Pathol 27:365-71. 2003..We recommend this basal cell cocktail for routine Pca diagnostic work-up... - High-density tissue microarrayWoo Ho Kim
Am J Surg Pathol 26:1236-8; discusson 1237-8. 2002 - Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancerRajal B Shah
Deparment of Pathology and Urology, University of Michigan School of Medicine and Comprenhensive Cancer Center, Ann Arbor, Michigan 48109, USA
Am J Surg Pathol 26:1161-8. 2002..p63 may be used as an alternative to 34betaE12 stain for difficult prostate lesions... - alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiationRainer Kuefer
Department of Pathology, University of Michigan Medical School, Ann Arbor 48109 0602, USA
Am J Pathol 161:841-8. 2002..Taken together, these data suggest that AMACR expression is not hormone-dependent but may in fact be a marker of tumor differentiation... - Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarraysAngelo M De Marzo
Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231-1000, USA
Hum Pathol 33:756-60. 2002.... - Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survivalDinesh S Rao
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
J Clin Invest 110:351-60. 2002..HIP1 represents a putative prognostic factor for prostate cancer and a potential therapy target in prostate as well as colon cancers... - Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesionsMing Zhou
Department of Pathology, University of Michigan School of Medicine, Ann Arbor, USA
Am J Surg Pathol 26:926-31. 2002..In conclusion, our study suggests that AMACR is potentially an important tumor marker for several cancers and their precursor lesions, especially those linked to high-fat diets... - Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugateSarajane Ross
Department of Pathology, Genentech, Inc, South San Francisco, California 94080, USA
Cancer Res 62:2546-53. 2002..Our results strongly suggest that maytansinoid-conjugated anti-PSCA monoclonal antibodies should be evaluated as a therapeutic modality for patients with advanced prostate cancer... - Effect of finasteride on risk of prostate cancer: how little we really knowMark A Rubin
Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Cell Biochem 91:478-82. 2004..Confirmation of a spurious tumor grade "inflation" will make the conclusions of this study clearer and define the benefits of finasteride chemoprevention in a more favorable light... - The role of metastasis-associated protein 1 in prostate cancer progressionMatthias D Hofer
Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
Cancer Res 64:825-9. 2004..In summary, this study identified an association of MTA1 expression and prostate cancer progression... - Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancerChandan Kumar-Sinha
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109-0602, USA
Am J Pathol 164:787-93. 2004..Taken together, our studies suggest that AMACR activity is increased in prostate cancer relative to benign epithelia and suggests that monitoring AMACR activity levels in prostate needle biopsies may have clinical applications... - Autoantibody signatures in prostate cancerXiaoju Wang
Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
N Engl J Med 353:1224-35. 2005..The remaining phage peptides were generated from untranslated sequences. CONCLUSIONS: Autoantibodies against peptides derived from prostate-cancer tissue could be used as the basis for a screening test for prostate cancer... - Translational crossroads for biomarkersRobert C Bast
University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 11:6103-8. 2005.... - What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer?Aurelien Descazeaud
Department of Urology and Pathology, INSERMEMI03 3, Hopital Henri Mondor, Creteil, France
Eur Urol 48:911-5. 2005..This survey-based study examines what information urologists are extracting from prostate needle biopsy reports, and what they need for clinical management of prostate cancer (PC) patients... - Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cellsCharles J Dimitroff
Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women s Hospital, Boston, Massachusetts, USA
Cancer Res 65:5750-60. 2005..These findings implicate a functional role of PSGL-1 in the bone tropism of prostate tumor cells and establish a new perspective into the molecular mechanism of human prostate tumor metastasis... - Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific deathMark A Rubin
Department of Pathology Amory 3 195, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
Cancer Epidemiol Biomarkers Prev 14:1424-32. 2005..This is the first study to show that AMACR expression is significantly associated with prostate cancer progression and suggests that not all surrogate end points may be optimal to define biomarkers of aggressive prostate cancer... - Reg IV: a promising marker of hormone refractory metastatic prostate cancerZhennan Gu
Department of Statistics, Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Clin Cancer Res 11:2237-43. 2005..In comparison, it is not expressed by any normal prostate specimens and only at low levels in approximately 40% of primary tumors. These data support Reg IV as a candidate marker for hormone refractory metastatic prostate cancer... - Benign positive margins after radical prostatectomy means a poor prognosis--conMark A Rubin
Urology 65:221-3. 2005 - Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimensTara-Jane Browne
Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA
Hum Pathol 35:1462-8. 2004..However, a limitation of this approach is the loss of tissue in these small lesions, suggesting that combining AMACR and the BCC on a single slide would be superior to using either marker separately... - Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy programRajal B Shah
Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
Cancer Res 64:9209-16. 2004..An appreciation of this heterogeneity is critical to evaluating diagnostic and prognostic biomarkers as well as to designing therapeutic targets for advanced disease... - Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitorsMatthias D Hofer
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Neoplasia 6:503-12. 2004..2-fold downregulation). Taken together, this study suggests that only a small subset of PCas may be amenable to tyrosine kinase inhibitors specific for PDGFR... - Using molecular markers to predict outcomeMark A Rubin
Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
J Urol 172:S18-21; discussion S21-2. 2004..Developing molecular tests to predict prostate cancer progression requires first defining meaningful clinical end points and defining strategies to take advantage of emerging technology... - Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferationsRajal B Shah
Department of Pathology, University of Michigan School of Medicine, Ann Arbor 48109, USA
Am J Clin Pathol 122:517-23. 2004..The cocktail provides a simple, cost-effective improvement in basal cell immunohistochemical analysis of difficult prostate lesions... - JAGGED1 expression is associated with prostate cancer metastasis and recurrenceSandro Santagata
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Res 64:6854-7. 2004.... - Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancerArun Sreekumar
Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109-0602, USA
J Natl Cancer Inst 96:834-43. 2004..CONCLUSION: Assays to detect a humoral immune response against AMACR may have the potential to supplement PSA screening in identifying patients with clinically significant prostate cancer, especially those with intermediate PSA levels... - Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumorsPamela L Paris
Comprehensive Cancer Center, University of California at San Francisco, 94115, USA
Hum Mol Genet 13:1303-13. 2004..Moreover, comparison with an independent set of metastases revealed approximately 40 candidate markers associated with metastatic potential. Copy number aberrations at these loci may define metastatic genotypes... - Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurementsMark A Rubin
Department of Pathology, Brigham and Women s Hospital, and the Harvard Medical School, Boston, Massachusetts 02115, USA
Am J Pathol 164:831-40. 2004..In the future, the AMACR AQUA Z-score may be useful in the automated screening and evaluation of prostate tissue biomarkers... - alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancerMark A Rubin
Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
JAMA 287:1662-70. 2002..Molecular profiling of prostate cancer has led to the identification of candidate biomarkers and regulatory genes. Discoveries from these genome-scale approaches may have applicability in the analysis of diagnostic prostate specimens...
Research Grants
- "Molecular Signatures of Lethal and Indolent Prostate Cancer"Mark A Rubin; Fiscal Year: 2010..At th conclusion of this proposal, we expect to have refined and fully validated molecular predictors of PCA deat as well as indolent PCA that is appropriate for further clinical development. ..
- "Molecular Signatures of Lethal and Indolent Prostate Cancer"Mark Rubin; Fiscal Year: 2009..At th conclusion of this proposal, we expect to have refined and fully validated molecular predictors of PCA deat as well as indolent PCA that is appropriate for further clinical development. ..
- Prostate Cancer Harbinger GenesMark Rubin; Fiscal Year: 2006..abstract_text> ..
- "Molecular Signatures of Lethal and Indolent Prostate Cancer"Mark Rubin; Fiscal Year: 2006..At the conclusion of this proposal, we expect to have refined and fully validated molecular predictors of PCA death as well as indolent PCA that is appropriate for further clinical development. ..
- Towards Understanding Prostate Cancer HeterogeneityMark A Rubin; Fiscal Year: 2010..Finally, we will determine if FISH assays (or other in situ tests) can be employed as a prognostic biomarker. ..